Welcome to the Lee laboratory. Our aim is to identify molecular drivers and biological properties of prostate and bladder cancer that may be exploited for the development of new and effective treatments. In our research we employ cutting-edge technologies including mouse and human epithelial transformation systems; functional genomics; multi-omic data integration; high-throughput screening; small molecule drug discovery; and immuno-oncology to develop new approaches to stratify and treat prostate and bladder cancer.
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. DeLucia DC, Cardillo TM, Ang LS, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK.
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.
Diana's paper is published in Clinical Cancer Research via OnlineFirst! Thanks and congratulations to all of our collaborators!
John is selected for the Society for Basic Urologic Research 2020 Young investigator Award.
Diana's abstract submitted for the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting is accepted for a Travel Award and Poster Presentation! Congratulations!